View More Recent Stories
-
Moderna (MRNA) Strength tied to Speculation About New Coronavirus
-
Moderna stock rises following RFK Jr's comments
-
Novavax (NVAX) call put ratio 8.1 calls to 1 put as share price up 12.8%
-
Novavax (NVAX) Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50M Milestone
-
H.C. Wainwright Reiterates Buy Rating on Novavax (NVAX)
-
Novavax (NVAX) Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza
-
Novavax (NVAX) Sells Czech Republic Manufacturing Site to Novo Nordisk for $200M
-
Moderna (MRNA) +9% as Jefferies says the market is nearing short term 'peak RFK negativity'
-
Novavax (NVAX) PT Lowered to $22 at B.Riley
-
H.C. Wainwright Reiterates Buy Rating on Novavax (NVAX)
-
Novavax (NVAX) Tops Q3 EPS by 7c ; Offers Guidance
-
Novavax (NVAX) Announces FDA Removed Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
-
Increasing unusual put option volume: BEN XLB AEM RACE EMB NXPI LYB ADM NVAX MSTX CME HIMS AUG
-
Novavax (NVAX) October 11 calls and October 14 calls active as share price down 19%
-
Novavax (NVAX) PT Lowered to $25 at Jefferies
-
Novavax (NVAX) PT Lowered to $14 at BofA Securities 'to reflect delays in phase 3 CIC/standalone flu trial'
-
Novavax (NVAX): FDA placed clinical hold on IND for COVID-19-Influenza combination and stand-alone influenza vaccine candidates
-
Novavax (NVAX) call put ratio 14.4 calls to 1 put with focus on 23K contracts of October 35 calls
-
Novavax (NVAX) PT Raised to $26 at B.Riley
-
Novavax's (NVAX) Updated 2024-2025 Nuvaxovid COVID-19 Vaccine Receives Authorization in the EU
-
Novavax (NVAX) + 22% on bullish comments at Jefferies
-
Novavax (NVAX) Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of Research & Development
-
Novavax (NVAX) 2024-2025 Formula COVID-19 Vaccine Available at Major Pharmacies Across the U.S.
-
Novavax (NVAX) 2024-2025 Formula COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.
-
FDA Authorizes Updated Novavax (NVAX) COVID-19 Vaccine to Better Protect Against Currently Circulating Variants
-
Novavax (NVAX) shares tumble as Q2 results miss estimates, guidance cut
-
Novavax (NVAX) Reports Q2, Issues Operational Update
-
Novavax shares slide as JPMorgan cuts the stock to Underweight on overvaluation concerns
-
JPMorgan Downgrades Novavax (NVAX) to Underweight
-
Novavax (NVAX) PT Lowered to $31 at Jefferies ahead of Q2
-
Novavax (NVAX) Submits Application to Health Canada for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine
-
Novavax (NVAX) Submits Application to European Medicines Agency for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine
-
Novavax (NVAX) Submits Application to U.S. FDA for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine

